THAR: tharimmune.com Price/Earnings to Growth Multiple
The implementation of energy-efficient systems and strict waste control support the current trend, with the latest parameter standing at 0.00. The P/E ratio and EPS growth correlation help identify the asset's undervaluation. Tharimmune, Inc. (THAR) business development remains independent of GDP phases, relying instead on clinical successes, while expansion potential is based on securing major institutional partners for joint drug trials.
Tharimmune, Inc. (THAR) - metric breakdowns and financial figures
- share price and consensus valuation forecast:
- market capitalization information:
- book value of equity indicators:
- business debt structure and liquidity details:
Debt to Capital Tharimmune, Inc.|THAR - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio tharimmune.com|THAR - Company Aggregate Debts|Debt to Net Assets Ratio Tharimmune Corp|THAR - Company Long-Term Debts|Company Short-Term Debts Tharimmune|Intermediate Coverage Ratio tharimmune.com
- company profitability and valuation multiples indicators:
THAR - Net Profit|Company Profit Forecast Tharimmune, Inc.|THAR - Price to Earnings Ratio|Projected Price to Earnings Tharimmune Corporation|THAR - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Tharimmune Corp|THAR - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Tharimmune|THAR - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months tharimmune.com|THAR - Earnings growth in current year|Expected net earnings per share growth next year Tharimmune, Inc.
General company analysis:Tharimmune Inc, THAR
The PEG ratio assesses the fairness of an asset's market value by relating the P/E multiple to earnings growth rates. By analyzing P/E dynamics relative to profit growth, an investor determines the degree of a company's undervaluation. A value below one signals growth potential that exceeds the current share price. For Tharimmune, Inc. (THAR), this indicator is critical due to high capital burn during early-stage trials. The metric allows for balancing pre-commercial period risks against future expansion rates.
Competing companies
ONC (BeiGene Ltd.) - Growth-Adjusted Payback Ratio|PEG Multiple HALO (Halozyme Inc.)|RVMD - Price/Earnings to Growth Multiple|AAPG: Price/Earnings to Growth Multiple|CGON - PEG Multiple|UroGen Pharma (URGN) - Price/Earnings to Growth Ratio|Bicara Therapeutics Inc - Growth-Adjusted Payback Ratio|PSNL (Personalis Corp) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Erasca Oncology ERAS|Price/Earnings to Growth Multiple DCTH (Delcath Systems, Inc.)|Company Value to Earnings Growth Ratio YMAB|PEG Multiple AURA (Aura Biosciences)|Growth-Adjusted Payback Ratio CADL|Accuray Inc. - PEG Multiple|SLS - PEG Multiple|Actuate Therapeutics, Inc. (ACTU) - Price/Earnings to Growth Ratio|citiusonc.com - Growth-Adjusted Payback Ratio|HURA (TuHURA Biosciences Inc.) - PEG Multiple|Protara Therapeutics Inc (TARA) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Fate Therapeutics Corp (FATE)|Price/Earnings to Growth Multiple aadibio.com WHWK|Price/Earnings to Growth Ratio TScan Therapeutics, Inc. TCRX|CSBR - Price/Earnings to Growth Multiple|XBIT: Price/Earnings to Growth Multiple|CVM - PEG Multiple|OS Therapies Inc (OSTX) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio RADX|ARTV (Artiva Biotherapeutics Inc.) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Adlai Nortye Limited ANL|Price/Earnings to Growth Multiple VERU (Veru)|TPST (Tempest Therapeutics Inc) - Growth-Adjusted Payback Ratio|PEG Multiple XLO (Xilio Therapeutics)|Growth-Adjusted Market Cap to Net Income Renovaro Biosciences (RENB)|MURA - Price/Earnings to Growth Ratio|KAPA (Kairos Pharma Ltd) - Growth-Adjusted P/E Ratio|OKUR: PEG Multiple|Price/Earnings to Growth Multiple CytoMed Therapeutics Limited|Price/Earnings to Growth Multiple CRIS|Apollomics Corp (APLM) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple ADVB (Advanced Biomed Inc)|Company Value to Earnings Growth Ratio GNPX|PEG Multiple CLDI (Calidi Biotherapeutics, Inc.)|Growth-Adjusted Payback Ratio SBFM|Xenetic Bio - PEG Multiple|SLRX - PEG Multiple|Purple Biotech (PPBT) - Price/Earnings to Growth Ratio|American Oncology Network, Inc. - Growth-Adjusted Payback Ratio|BGNE (BeiGene) - PEG Multiple|Price/Earnings to Growth Multiple Checkpoint Therapeutics Inc. (CKPT)|PEG Multiple ELEV|PEG Multiple icadmed.com (ICAD)|Price/Earnings to Growth Ratio Ikena Oncology IKNA|NTBL: Growth-Adjusted P/E Ratio|Viracta - PEG Multiple|MorphoSys Inc (MOR) - Price/Earnings to Growth Multiple|NAYA: PEG Multiple|Price to Earnings Adjusted for Growth Rate Ascentage (AAPGV)
